Clinical Trial Update: A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA [Phase 3]

View source ↗

Summary

Phase 3 safety, efficacy, and pharmacokinetics study of tofacitinib in pediatric patients with systemic juvenile idiopathic arthritis has completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis
• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis Juvenile Idiopathic | Phase 3 | Status: COMPLETED | Results posted: 2025-06-03